High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy

Current Opinion in Investigational Drugs

Volumn 6, Issue 9, 2005, Pages 907-919

  Schmitz, Gerd ^a   Langmann, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Apolipoprotein A I mimetics; Atherosclerosis; ATP binding cassette transporters; High density lipoprotein metabolism; Niacin; Nuclear receptors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ALCOHOL; APOLIPOPROTEIN A1; CARDIOVASCULAR AGENT; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CYCLOSPORIN; ESTROGEN; FIBRIC ACID DERIVATIVE; GW 610742; GW 683965A; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHOLIPID; PROBUCOL; PROTEIN; REPRESSOR PROTEIN; RETINOID; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL MEMBRANE; DRUG MECHANISM; DRUG TARGETING; HUMAN; INTRACELLULAR TRANSPORT; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARDIOVASCULAR DISEASES; DNA-BINDING PROTEINS; HEPATOCYTES; HEPTANOIC ACIDS; HOMEOSTASIS; HUMANS; INTESTINAL MUCOSA; KIDNEY; LIPID METABOLISM; LIPOPROTEINS, HDL; MACROPHAGES; NIACIN; PYRROLES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 24644457140     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Dean M, Allikmets R: Complete characterization of the human ABC gene family. J Bioenerg Biomembr (2001) 33(6):475-479.
2. Schmitz G, Kaminski WE, Orso E: ABC transporters in cellular lipid trafficking. Curr Opin Lipidol (2000) 11(5):493-501.
3. Schmitz G, Langmann T, Heimerl S: Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res (2001) 42(10):1513-1520.
4. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G: Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): Evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun (1999) 257(1):29-33.
5. Liao H, Langmann T, Schmitz G, Zhu Y: Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler Thromb Vasc Biol (2002) 22(1):127-132.
6. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med (2004) 350(13):1296-1303.
7. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290(5497):1771-1775.
8. Lu K, Lee MH, Patel SB: Dietary cholesterol absorption; more than just bile. Trends Endocrinol Metab (2001) 12(7):314-320.
9. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE et al: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet (1999) 22(4):347-351.
10. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O et al: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 22(4):336-345.
11. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet (1999) 22(4):352-355.
12. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, Gotz A, Chambenoit O, Diederich W, Langmann T, Spruss T et al: Transport of lipids from Golgi to plasma membrane is defective in Tangier disease patients and ABC1-deficient mice. Nat Genet (2000) 24(2):192-196.
13. Brewer HB Jr, Santamarina-Fojo S: New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol (2003) 91(7A):3E-11E.
14. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A: Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest (2004) 114(9):1343-1353.
15. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G: ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA (2000) 97(2):817-822.
16. Bellincampi L, Simone ML, Motti C, Cortese C, Bernardini S, Bertolini S, Calandra S: Identification of an alternative transcript of ABCA1 gone in different human cell types. Biochem Biophys Res Commun (2001) 283(3):590-597.
17. Huuskonen J, Abedin M, Vishnu M, Pullinger CR, Baranzini SE, Kane JP, Fielding PE, Fielding CJ: Dynamic regulation of alternative ATP-binding cassette transporter A1 transcripts. Biochem Biophys Res Commun (2003) 306(2):463-468.
18. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, Tall AR: Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem (2003) 278(39):37368-37374.
19. Wang N, Chen W, Linsel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall AR: A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest (2003) 111(1):99-107.
20. Roosbeek S, Peelman F, Verhee A, Labeur C, Caster H, Lensink MF, Cirulli C, Grooten J, Cochet C, Vandekerckhove J, Amoresano A et al: Phosphorylation by protein kinase CK2 modulates the activity of the ATP binding cassette A1 transporter. J Biol Chem (2004) 279(36):37779-37788.
21. Tang C, Vaughan AM, Oram JF: Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem (2004) 279(9):7622-7628.
22. Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang YZ, Zhang LH, James E, Wilson JE, Francone O et al: ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest (2002) 82(3):273-283.
23. Feng B, Tabas I: ABCA1-mediated cholesterol efflux is defective in free cholesterol-loaded macrophages. Mechanism involves enhanced ABCA1 degradation in a process requiring full NPC1 activity. J Biol Chem (2002) 277(45):43271-43280.
24. Wang Y, Oram JF: Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem (2002) 277(7):5692-5697.
25. Wang Y, Kurdi-Haidar B, Oram JF: LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res (2004) 45(5):972-980.
26. Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heinecke JW, Oram JF: Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes (2005) 54(7):2198-2205.
27. 3 inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42. Atherosclerosis (2001) 159(2):313-324.
28. Tsukamoto K, Hirano K, Tsujii K, Ikegami C, Zhongyan Z, Nishida Y, Ohama T, Matsuura F, Yamashita S, Matsuzawa Y: ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem Biophys Res Commun (2001) 287(3):757-765.
29. Tsukamoto K, Hirano K, Yamashita S, Sakai N, Ikagami C, Zhang Z, Matsuura F, Hiraoka H, Matsuyama A, Ishigami M, Matsuzawa Y: Retarded intracellular lipid transport associated with reduced expression of Cdc42, a member of Rho-GTPases, in human aged skin fibroblasts: A possible function of Cdc42 in mediating intracellular lipid transport. Arterioscler Thromb Vasc Biol (2002) 22(11):1899-1904.
30. 2-syntrophin/utrophin complex. Biochem Biophys Res Commun (2002) 293(2):759-765.
31. Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, Yokota T, Takeda S, Amachi T, Matsuo M, Kioka N, Ueda K: α1-syntrophin modulates turnover of ABCA1. J Biol Chem (2004) 279(15):16091-15095.
32. Engel T, Lueken A, Bode G, Hobohm U, Lorkowski S, Schlueter B, Rust S, Cullen P, Pech M, Assmann G, Seedorf U: ADP-ribosylation factor (ARF)-like 7 (ARL7) is induced by cholesterol loading and participates in apolipoprotein AI-dependent cholesterol export. FEBS Lett (2004) 566(1-3):241-246.
33. Bared SM, Buechler C, Boettcher A, Dayoub R, Sigruener A, Grandl M, Rudolph C, Dada A, Schmitz G: Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells. Mol Biol Cell (2004) 15(12):5399-5407.
34. Huang L, Kuo YM, Gitschier J: The pallid gone encodes a novel, syntaxin 13-interacting protein involved in platelet storage pool deficiency. Nat Genet (1999) 23(3):329-332.
35. Nofer JR, Herminghaus G, Brodde M, Morgenstern E, Rust S, Engel T, Seedort U, Assmann G, Bluethmann H, Kehrel BE: Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem (2004) 279(32):34032-34037.
36. Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G: Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem (2003) 49(2):230-238.
37. Krieger M: Charting the fate of the "good cholesterol": Identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem (1999) 68:523-558.
38. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X et al: Ectopic β-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature (2003) 421(6918):75-79.
39. Bjorkhem I, Meaney S, Diczfalusy U: Oxysterols in human circulation: Which role do they have? Curr Opin Lipidol (2002) 13(3):247-253.
40. Neufeld EB, Demosky SJ Jr, Stonik JA, Combs C, Remaley AT, Duverger N, Santamarina-Fojo S, Brewer HB Jr: The ABCA1 transporter functions on the basolateral surface of hepatocytes. Biochem Biophys Res Commun (2002) 297(4):974-979.
41. Silver DL: SR-BI and protein-protein interactions in hepatic high density lipoprotein metabolism. Rev Endocr Metab Disord (2004) 5(4):327-333.
42. Ito T: Physiological function of ABCG1. Drug News Perspect (2003) 16(8):490-492.
43. Kennedy MA, Barrera GC, Nakamura K, Baladan A, Tarr P, Fishbein MC, Frank J, Francone O, Edwards PA: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab (2005) 1(2):121-131.
44. Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH: Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest (2002) 110(5):659-669.
45. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH: Disruption of ABCG5 and ABCG8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA (2002) 99(25):16237-16242.
46. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH: Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 110(5):671-680.
47. Kullak-Ublick GA, Stieger B, Meier PJ: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology (2004) 126(1):322-342.
48. Fitzgerald ML, Moore KJ, Freeman MW: Nuclear hormone receptors and cholesterol trafficking: The orphans find a new home. J Mol Med(2002) 80(5):271-281.
49. Elferink RO, Groan AK: Genetic defects in hepatobiliary transport. Biochim Biophys Acta (2002) 1586(2):129-145.
50. Handschin C, Meyer UA: Regulatory network of lipid-sensing nuclear receptors: Roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys (2005) 433(2):387-396.
51. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β. J Biol Chem (2002) 277(21):18793-18800.
52. Duan LP, Wang HH, Wang DQ: Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters ABCG5 and ABCG8 in mice. J Lipid Res (2004) 45(7):1312-1323.
53. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Rhein M, Wendler W, Lottspeich F, Hochleitner EO, Orso E, Schmitz G: Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J Biol Chem (2005) 280(2):1306-1320.
54. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao, X, Iyer SP, Lam MH, Lund EG, Detmers PA et al: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem (2004) 279(32):33586-33592.
55. Hansen GH, Pedersen J, Niels-Christiansen LL, Immerdal L, Danielsen EM: Deep-apical tubules: Dynamic lipid-raft microdomains in the brush-border region of enterocytes. Biochem J (2003) 373(1):125-132.
56. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L et al: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303(5661):1201-1204.
57. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crone JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP et al: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA (2005) 102(23):8132-8137.
58. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem (2005) 280(13):12710-12720.
59. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groan AK, Kuipers F: Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res (2005) 46(3):526-534.
60. Windmueller HG, Herbert PN, Levy RI: Biosynthesis of lymph and plasma lipoprotein apoproteins by isolated perfused rat liver and intestine. J Lipid Res (1973) 14(2):215-223.
61. Nowicka G, Bruning T, Bottcher A, Kahl G, Schmitz G: Macrophage interaction of HDL subclasses separated by free flow isotachophoresis. J Lipid Res (1990) 31(11):1947-1963.
62. Murthy S, Born E, Mathur SN, Field FJ: LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res (2002) 43(7):1054-1064.
63. Drobnik W, Lindenthal B, Lieser B, Ritter M, Weber TC, Liebisch G, Giesa U, Igel M, Borsukova H, Buchler C, Fung-Leung WP et al: ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Gastroenterology (2001) 120(5):1203-1211.
64. Mulligan JD, Flowers MT, Tebon A, Bitgood JJ, Wellington C, Hayden MR, Attie AD: ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem (2003) 278(15):13356-13366.
65. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289(5484):1524-1529.
66. van Tol A, 't Hooft FM, van Gent T, Dallinga-Thie GM: HDL subfractions, HDL receptors and HDL turnover. Adv Exp Med Biol (1987) 210:15-21.
67. Keane WF: The role of lipids in renal disease: Future challenges. Kidney Int Suppl (2000) 75:S27-S31.
68. Hammad SM, Barth JL, Knaak C, Argraves WS: Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem (2000) 275(16):12003-12008.
69. 12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med (1999) 5(6):656-661.
70. Ritter M, Buechler C, Boettcher A, Barlage S, Schmitz-Madry A, Orso E, Bared SM, Schmiedeknecht G, Baehr CH, Fricker G, Schmitz G: Cloning and characterization of a novel apolipoprotein A-I binding protein, AI-BP, secreted by cells of the kidney proximal tubules in response to HDL or ApoA-I. Genomics (2002) 79(5):693-702.
71. Van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, Bottcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ, Schmitz G: Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA (2002) 99(9):6298-6303.
72. Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK: Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem (2004) 279(23):24044-24052.
73. Vedhachalam C, Liu L, Nickel M, Dhanasekaran P, Anantharamaiah GM, Lund-Katz S, Rothblat GH, Phillips MC: Influence of ApoA-I structure on the ABCA1-mediated efflux of cellular lipids. J Biol Chem (2004) 279(48):49931-49939.
74. Haidar B, Denis M, Marcil M, Krimbou L, Genest J Jr: Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem (2004) 279(11):9963-9969.
75. Arakawa R, Hayashi M, Remaley AT, Brewer BH, Yamauchi Y, Yokoyama S: Phosphorylation and stabilization of ATP binding cassette transporter A1 by synthetic amphiphilic helical peptides. J Biol Chem (2004) 279(8):6217-6220.
76. Chroni A, Liu T, Fitzgerald ML, Freeman MW, Zannis VI: Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry (2004) 43(7):2126-2139.
77. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM: Human apolipoprotein A-I and A-I mimetic peptides: Potential for atherosclerosis reversal. Curr Opin Lipidol (2004) 15(6):645-649.
78. Schmitz G, Robenek H, Lohmann U, Assmann G: Interaction of high density lipoproteins with cholesteryl ester-laden macrophages: Biochemical and morphological characterization of cell surface receptor binding, endocytosis and resecretion of high density lipoproteins by macrophages. EMBO J (1985) 4(3):613-622.
79. Garin J, Diez R, Kieffer S, Dermine JF, Duclos S, Gagnon E, Sadoul R, Rondeau C, Desjardins M: The phagosome proteome: Insight into phagosome functions. J Cell Biol (2001) 152(1):165-180.
80. Schmitz G, Assmann G, Robenek H, Brennhausen B: Tangier disease: A disorder of intracellular membrane traffic. Proc Natl Acad Sci USA (1985) 82(18):6305-6309.
81. Heeren J, Grewal T, Laatsch A, Rottke D, Rinninger F, Enrich C, Beisiegel U: Recycling of apolipoprotein E is associated with cholesterol efflux and high density lipoprotein internalization. J Biol Chem (2003) 278(16):14370-14378.
82. Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB: Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization. Biochem Biophys Res Commun (2004) 320(3):860-867.
83. Wang N, Lan D, Chen W, Matsuura F, Tall AR: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA (2004) 101(26):9774-9779.
84. Vaughan AM, Oram JF: ABCG1 redistributes cell cholesterol to domains removable by HDL but not by lipid-depleted apolipoproteins. J Biol Chem (2005):doi:10.1074 /jbc.M505368200.
85. Costet P, Luo Y, Wang N, Tall AR: Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem (2000) 275(36):28240-28245.
86. Langmann T, Porsch-Ozcurumez M, Heimerl S, Probst M, Moehle C, Taher M, Borsukova H, Kielar D, Kaminski WE, Dittrich-Wengenroth E, Schmitz G: Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: Role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element. J Biol Chem (2002) 277(17):14443-14450.
87. Porsch-Ozcurumez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, Drobnik W, Honer C, Schumacher C, Schmitz G: The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem (2001) 276(15):12427-12433.
88. Meyers CD, Kashyap ML: Pharmacologic elevation of high-density lipoproteins: Recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol (2004) 19(4):366-373.
89. Asztalos BF, Brousseau ME, McNamara JR, Horvath KV, Roheim PS, Schaefer EJ: Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis (2001) 156(1):217-225.
90. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ: Change in α1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol (2003) 23(5):847-852.
91. Bottcher A, Schlosser J, Kronenberg F, Dieplinger H, Knipping G, Lackner KJ, Schmitz G: Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: Apolipoprotein and lipid composition of HDL subtractions. J Lipid Res (2000) 41(6):905-915.
92. Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, Okajima F, Saku K: Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis (2005) 178(1):199-205.
93. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin (2004) 20(8):1253-1268.
94. Rader DJ: Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol (2003) 92(4A):42J-49J.
95. Malik S, Kashyap ML: Niacin, lipids, and heart disease. Curr Cardiol Rep (2003) 5(6):470-476.
96. Carlson LA: Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract (2004) 58(7):706-713.
97. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 345(22):1583-1592.
98. Gibbons LW, Gonzalez V, Gordon N, Grundy S: The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med (1995) 99(4):378-385.
99. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 9(3):352-355.
100. Rubic T, Trottmann M, Lorenz RL: Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol (2004) 67(3):411-419.
101. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis (2002) 164(2):361-369.
102. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest (2001) 107(11):1423-1432.
103. Maejima T, Yamazakl H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun (2004) 324(2):835-839.
104. Zanotti I, Favari E, Sposito AC, Rothblat GH, Bernini F: Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun (2004) 321(3):670-674.
105. Sone H, Shimano H, Shu M, Nakakuki M, Takahashi A, Sakai M, Sakamoto Y, Yokoo T, Matsuzaka K, Okazaki H, Nakagawa Y et al: Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun (2004) 316(3):790-794.
106. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther (2004) 311(1):420-425.
107. Wong J, Quinn CM, Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver X receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol (2004) 24(12):2365-2371.
108. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 22(5):717-726.
109. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. J Am Med Assoc (2001) 285(12):1585-1591.
110. Khan MA, St Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care (2002) 25(4):708-711.
111. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB et al: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 7(1):53-58.
112. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P: A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell (2001) 7(1):161-171.
113. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ and γ. J Clin Invest (2004) 114(11):1564-1576.
114. Lamon-Fava S, Micherone D: Regulation of apoA-I gene expression: Mechanism of action of estrogen and genistein. J Lipid Res (2004) 45(1):106-112.
115. Srivastava RA: Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: A possible mechanism of atheroprotection by estrogen. Mol Cell Biochem (2002) 240(1-2):67-73.
116. Hendriks HF, Veenstra J, van Tol A, Groener JE, Schaafsma G: Moderate doses of alcoholic beverages with dinner and postprandlal high density lipoprotein composition. Alcohol (1998) 33(4):403-410.
117. Beulens JW, Sierksma A, van Tol A, Foumier N, van Gent T, Paul JL, Hendriks HF: Moderate alcohol consumption increases cholesterol efflux mediated by ABCA1. J Lipid Res (2004) 45(9):1716-1723.
118. Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH: Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol (2004) 24(12):2345-2350.
119. Wu CA, Tsujita M, Hayashi M, Yokoyama S: Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem (2004) 279(29):30168-30174.
120. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S: On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res (2005) 46(1):154-162.
121. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation (1994) 57(10):1479-1483.
122. Le Goff W, Peng DQ, Settle M, Brubaker G, Morton RE, Smith JD: Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2004) 24(11):2155-2161.
123. Redlich CA, Chung JS, Cullen MR, Blaner WS, Van Bennekum AM, Berglund L: Effect of long-term β-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis (1999) 145(2):425-432.
124. Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoub R, Heiduczek S, Grandl M, Dada A, Schmitz G: Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim Biophys Acta (2005) 1740(2):155-161.
125. Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, Tall AR: Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol Cell Biol (2003) 23(21):7756-7766.
126. Wagsater D, Dimberg J, Sirsjo A: Induction of ATP-binding cassette A1 by all-trans retinoic acid: Possible role of liver X receptor-α. Int J Mol Med (2003) 11(4):419-423.
127. Repa JJ, Mangelsdorf DJ: Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr Opin Biotechnol (1999) 10(6):557-563.
128. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ: Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev (2000) 14(22):2819-2830.
129. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R: Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res (2004) 45(8):1410-1417.
130. Quinet EM, Savio DA, Halpern AR, Chen L, Miller CP, Nambi P: Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J Lipid Res (2004) 45(10):1929-1942.
131. Schmitz G, Heimerl S, Langmann T: Zinc finger protein ZNF202 structure and function in transcriptional control of HDL metabolism. Curr Opin Lipidol (2004) 15(2):199-208.
132. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P: Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell (2003) 12(4):805-816.